Company Profile

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of inflammatory, cancer, and metabolic diseases. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its endpoints in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in approximately 1,500 patients in clinical studies to date.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Research and Development in Biotechnology (541711)

SIC:
Pharmaceutical Preparations (2834)

Contact Information

Investor Relations
T: (800) 716-4880
info@canfite.co.il

Company Contact
Can-Fite BioPharma Ltd.
10 Bareket Street, Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
Israel
Toll-Free: 800-716-4880
T: +972-3-9241114
F: +972-3-9249378
info@canfite.co.il